Article
Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities
2025-06-20
Abstract excerpt
<h4>SUMMARY</h4> The von Hippel-Lindau tumor suppressor (VHL) is a component of a ubiquitin ligase complex that normally controls cellular responses to hypoxia. Endogenous VHL is also utilized by proteolysis-targeting chimera (PROTAC) protein degraders, a promising class of anti-cancer agents. VHL is broadly essential for cell proliferation, yet it is a key tumor suppressor in renal cell carcinoma. To understand...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 572634ec-c8ad-5b4d-929b-70cb99b84865
- DOI
- 10.1101/2025.06.14.659649
